-
Phenotypic plasticity – Implications for tumours in bone J. Bone Oncol. (IF 3.4) Pub Date : 2024-03-01 Yujiao Han, Yibin Kang
Metastasis is a major contributor to cancer patient mortality. Tumour cells often develop phenotypic plasticity to successfully metastasize to different target organs. Recent progress in the study of bone metastasis has provided novel insight into the biological processes that drive the spread and growth of cancer cells in the bone. In this review, we provide a summary of how the bone marrow microenvironment
-
Pelvic bone tumor segmentation fusion algorithm based on fully convolutional neural network and conditional random field J. Bone Oncol. (IF 3.4) Pub Date : 2024-02-28 Shiqiang Wu, Zhanlong Ke, Liquan Cai, Liangming Wang, XiaoLu Zhang, Qingfeng Ke, Yuguang Ye
Pelvic bone tumors represent a harmful orthopedic condition, encompassing both benign and malignant forms. Addressing the issue of limited accuracy in current machine learning algorithms for bone tumor image segmentation, we have developed an enhanced bone tumor image segmentation algorithm. This algorithm is built upon an improved full convolutional neural network, incorporating both the fully convolutional
-
Large-Scale assessment of ChatGPT's performance in benign and malignant bone tumors imaging report diagnosis and its potential for clinical applications J. Bone Oncol. (IF 3.4) Pub Date : 2024-01-22 Fan Yang, Dong Yan, Zhixiang Wang
Objective This study was designed to delve into the complexities involved in diagnosing of benign and malignant bone tumors and to assess the potential of AI technologies like ChatGPT in improving diagnostic accuracy and efficiency. The study also explores the few-shot learning as a method to optimize ChatGPT's performance in specialized medical domains such as benign and malignant bone tumors diagnosis
-
Role of the osteocyte in bone metastasis – The importance of networking J. Bone Oncol. (IF 3.4) Pub Date : 2024-01-17 Stefaan W. Verbruggen
Metastatic bone disease is a complex condition resulting from the migration and colonization of cancer cells from their primary site to the bone microenvironment, where they typically develop a metastatic niche. Osteocytes, the most abundant cells in bone tissue and the master regulators of bone remodelling, are increasingly thought to play a crucial role in this process through intricate interactions
-
Epigenetic control of the vicious cycle J. Bone Oncol. (IF 3.4) Pub Date : 2024-01-12 Madeline B. Searcy, Rachelle W. Johnson
Epigenetic alterations, including DNA methylation and post translational modifications to histones, drive tumorigenesis and metastatic progression. In the context of bone metastasis, epigenetic modifications in tumor cells can modulate dissemination of cancer cells to the bone, tumor progression in the bone marrow, and may be associated with patient survival rates. Bone disseminated tumor cells may
-
LOX, but not LOXL2, promotes bone metastasis formation and bone destruction in triple-negative breast cancer J. Bone Oncol. (IF 3.4) Pub Date : 2024-01-05 Paola Di Mauro, Martine Croset, Lamia Bouazza, Philippe Clézardin, Caroline Reynaud
The primary function of the lysyl oxidase (LOX) family, including LOX and its paralogue LOX-like (LOXL)-2, is to catalyze the covalent crosslinking of collagen and elastin in the extracellular matrix. LOX and LOXL2 are also facilitating breast cancer invasion and metastatic spread to visceral organs (lungs, liver) in vivo. Conversely, the contribution of LOX and LOXL2 to breast cancer bone metastasis
-
Bones and guts – Why the microbiome matters J. Bone Oncol. (IF 3.4) Pub Date : 2024-01-05 Kelly F. Contino, Katherine L. Cook, Yusuke Shiozawa
The importance of the gut microbiota in human health has become increasingly apparent in recent years, especially when the relationship between microbiota and host is no longer symbiotic. It has long been appreciated that gut dysbiosis can be detrimental to human health and is associated with numerous disease states. Only within the last decade, however, was the gut microbiota implicated in bone biology
-
Reprogramming of glucose metabolism: Metabolic alterations in the progression of osteosarcoma J. Bone Oncol. (IF 3.4) Pub Date : 2024-01-04 Fangyu An, Weirong Chang, Jiayi Song, Jie Zhang, Zhonghong Li, Peng Gao, Yujie Wang, Zhipan Xiao, Chunlu Yan
Metabolic reprogramming is an adaptive response of tumour cells under hypoxia and low nutrition conditions. There is increasing evidence that glucose metabolism reprogramming can regulate the growth and metastasis of osteosarcoma (OS). Reprogramming in the progress of OS can bring opportunities for early diagnosis and treatment of OS. Previous research mainly focused on the glycolytic pathway of glucose
-
GHA-DenseNet prediction and diagnosis of malignancy in femoral bone tumors using magnetic resonance imaging J. Bone Oncol. (IF 3.4) Pub Date : 2023-12-29 Y. Yuguang, Yusi Chen, Daxin Zhu, Yifeng Huang, Ying Huang, Xiadong Li, Jianbing Xiahou
Background and objective Due to their aggressive nature and poor prognosis, malignant femoral bone tumors present considerable hurdles. Early treatment commencement is essential for enhancing vital and practical outcomes. In this investigation, deep learning algorithms will be used to analyze magnetic resonance imaging (MRI) data to identify bone tumors that are malignant. Methodology The study cohort
-
Association of androgen receptor and tumour-infiltrating lymphocytes with bone recurrence in triple-negative breast cancer J. Bone Oncol. (IF 3.4) Pub Date : 2023-12-23 Petra Ilenič, Ajda Herman, Erik Langerholc, Barbara Gazić, Boštjan Šeruga
-
Incidence and radiotherapy treatment patterns of complicated bone metastases J. Bone Oncol. (IF 3.4) Pub Date : 2023-12-23 Cedric Peters, Julie Vandewiele, Yolande Lievens, Marc van Eijkeren, Valérie Fonteyne, Tom Boterberg, Pieter Deseyne, Liv Veldeman, Wilfried De Neve, Chris Monten, Sabine Braems, Fréderic Duprez, Katrien Vandecasteele, Piet Ost
Background Despite the encouraging results of the SCORAD trial, single fraction radiotherapy (SFRT) remains underused for patients with complicated bone metastases with rates as low as 18–39%. We aimed to evaluate the incidence and treatment patterns of these metastases in patients being referred to a tertiary centre for palliative radiotherapy. Materials and methods We performed a retrospective review
-
Essential genes analysis reveals small ribosomal subunit protein eS28 may be a prognostic factor and potential vulnerability in osteosarcoma J. Bone Oncol. (IF 3.4) Pub Date : 2023-12-15 Chao Liang, Juan Zhou, Yongjie Wang, Yin Sun, Jin Zhou, Lan Shao, Zhichang Zhang, Wangjun Yan, Zhiyan Liu, Yang Dong
Background Osteosarcoma, the most common primary malignant bone tumor, is currently treated with surgery combined with chemotherapy, but the limited availability of targeted drugs contributes to a poor prognosis. Identifying effective therapeutic targets is crucial for improving the prognosis of osteosarcoma patients. Methods We screened the DepMap database to identify essential genes as potential
-
Surgical Options for Aggressive Vertebral Hemangiomas:A case series, literature review and treatment recommendations J. Bone Oncol. (IF 3.4) Pub Date : 2023-11-25 Mohamed Diaty Diarra, Zengjie Zhang, Zhan Wang, Eloy Yinwang, Hengyuan Li, Shengdong Wang, Peng Lin, Xin Huang, Zhaoming Ye
Purpose We retrospectively study twenty-nine surgical cases of aggressive vertebral hemangiomas (AVHs) with neurological deficits and extradural compression to determine the optimal surgical treatment strategy for AVHs at a single institution. Methods Patients with AVHs with neurological deficits who underwent partial tumor resection plus decompression with or without vertebroplasty (VP), and radiotherapy
-
Intraosseous conventional central chondrosarcoma does not metastasise irrespective of grade in pelvis, scapula and in long bone locations J. Bone Oncol. (IF 3.4) Pub Date : 2023-11-10 Minna K. Laitinen, Joachim Thorkildsen, Guy Morris, Vineet Kurisunkal, Jonathan D. Stevenson, Michael C. Parry, Lee M. Jeys
Background Histological grade has been regarded as the most important prognostic factor in conventional central chondrosarcoma. To evaluate whether the presence of an extraosseous tumour component is associated with a decreased metastasis-free survival or disease-specific survival and alternatively to develop a simple prognostic and clinical decision-making tool. Material and methods We searched two
-
Targeting transforming growth factor beta signaling in metastatic osteosarcoma J. Bone Oncol. (IF 3.4) Pub Date : 2023-11-08 Rongrong Ge, Gavin M. Huang
Osteosarcoma is a rare type of bone cancer, and half of the cases affect children and adolescents younger than 20 years of age. Despite intensive efforts to improve both chemotherapeutics and surgical management, the clinical outcome for metastatic osteosarcoma remains poor. Transforming growth factor β (TGF-β) is one of the most abundant growth factors in bones. The TGF-β signaling pathway has complex
-
Long non-coding RNA PVT1 (PVT1) affects the expression of CCND1 and promotes doxorubicin resistance in osteosarcoma cells J. Bone Oncol. (IF 3.4) Pub Date : 2023-11-07 Zi Li, Jia-Ming Tian, Yi Chu, Hong-Yi Zhu, Jun-Jie Wang, Jun Huang
Background Acquired drug-resistance is the major risk factor for poor prognosis and short-term survival in patients with osteosarcoma (OS). Accumulating evidence has revealed that long noncoding RNAs (lncRNAs), including plasmacytoma variant translocation 1 (PVT1), play potential regulatory roles in the malignant development of OS. Considering the subcellular distribution of PVT1 as both nuclear and
-
Novel_circ_003686 regulates the osteogenic differentiation of MSCs in patients with myeloma bone disease through miR-142-5p/IGF1 axis J. Bone Oncol. (IF 3.4) Pub Date : 2023-11-03 Ling Qiu, Lei Ma, Dan Chen, Nan Zhang, Jiao Cai, Qian Zhang, Xiao Wang, Hai Yi, Hao Yao, Fang-Yi Fan
Objectives Circ_003686 is a novel_circRNA with abnormally low expression found in the samples of multiple myeloma bone disease (MBD) patients. The current research intended to investigate the effects of novel_circ_003686 in osteogenesis-induced differentiation of bone marrow mesenchymal stem cells (BMSCs) in MBD. Methods BMSCs were extracted from MBD patients and normal participants, the pcDNA3.1 encoding
-
Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa J. Bone Oncol. (IF 3.4) Pub Date : 2023-11-03 Ahmad Assi, Mohamad Farhat, Maria Catherine Rita Hachem, Ziad Zalaquett, Marven Aoun, Mohammad Daher, Amer Sebaaly, Hampig-Raphaël Kourie
Osteosarcoma (OS) is an aggressive primary bone malignancy that metastasizes rapidly. The standard of care has changed little over the previous four decades, and survival rates have plateaued. In this context, tyrosine kinase inhibitors (TKIs) emerge as potential treatments. A literature search was conducted to collect data related to receptor tyrosine kinase genetic alterations and expression in OS
-
A fusion of VGG-16 and ViT models for improving bone tumor classification in computed tomography J. Bone Oncol. (IF 3.4) Pub Date : 2023-11-02 Weimin Chen, Muhammad Ayoub, Mengyun Liao, Ruizheng Shi, Mu Zhang, Feng Su, Zhiguo Huang, Yuanzhe Li, Yi Wang, Kevin K.L. Wong
Background and Objective Bone tumors present significant challenges in orthopedic medicine due to variations in clinical treatment approaches for different tumor types, which includes benign, malignant, and intermediate cases. Convolutional Neural Networks (CNNs) have emerged as prominent models for tumor classification. However, their limited perception ability hinders the acquisition of global structural
-
Evaluation of pain related behaviors and disease related outcomes in an immunocompetent mouse model of prostate cancer induced bone pain J. Bone Oncol. (IF 3.4) Pub Date : 2023-10-30 Juan Miguel Jimenez-Andrade, Martha B. Ramírez-Rosas, Sun Hee Park, Renee Parker, Matthew R. Eber, Rebecca Cain, Mary Newland, Fang-Chi Hsu, Carol A. Kittel, Thomas J. Martin, Enriqueta Muñoz-Islas, Yusuke Shiozawa, Christopher M. Peters
Cancer-induced bone pain (CIBP) is the most common and devastating symptom of bone metastatic cancer that substantially disrupts patients’ quality of life. Currently, there are few effective analgesic treatments for CIBP other than opioids which come with severe side effects. In order to better understand the factors and mechanisms responsible for CIBP it is essential to have clinically relevant animal
-
The low and disproportionate utilization of antiresorptive therapy in patients with osseous metastasis J. Bone Oncol. (IF 3.4) Pub Date : 2023-10-14 Amil R. Agarwal, Christa L. LiBrizzi, Lauren Wessel, Savyasachi C. Thakkar, Adam S. Levin
Introduction Antiresorptive therapies are commonly utilized to mitigate and prevent skeletal-related-events in patients with metastatic osseous disease. However, limited data exists on the incidence or factors associated with prescription of antiresorptives or their effects on the incidence of pathologic fractures in patients with osseous metastatic disease. The aims of this study were to determine
-
The role of mitochondria-related lncRNAs in characterizing the immune landscape and supervising the prognosis of osteosarcoma J. Bone Oncol. (IF 3.4) Pub Date : 2023-10-05 Yiming Zhang, Nan Ru, Zhaowen Xue, Wenyi Gan, Ruilin Pan, Zelin Wu, Zihang Chen, Huajun Wang, Xiaofei Zheng
Mitochondrial damage is related to the functional properties of immune cells as well as to tumorigenesis and progression. Nevertheless, there is an absence concerning the systematic evaluation of mitochondria-associated lncRNAs (MALs) in the immune profile and tumor microenvironment of osteosarcoma patients. Based on transcriptomic and clinicopathological data from the TARGET database, MAL-related
-
Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms J. Bone Oncol. (IF 3.4) Pub Date : 2023-09-30 Gwenyth J. Joseph, Douglas B. Johnson, Rachelle W. Johnson
-
FemurTumorNet: Bone tumor classification in the proximal femur using DenseNet model based on radiographs J. Bone Oncol. (IF 3.4) Pub Date : 2023-09-15 Canyu Pan, Luoyu Lian, Jieyun Chen, Risheng Huang
Background & purpose For the best possible outcomes from therapy, proximal femur bone cancers must be accurately classified. This work creates an artificial intelligence (AI) model based on plain radiographs to categorize bone tumor in the proximal femur. Materials and methods A tertiary referral center's standard anteroposterior hip radiographs were employed. A dataset 538 images of the femur, including
-
What to choose in bone tumour resections? Patient specific instrumentation versus surgical navigation: a systematic review J. Bone Oncol. (IF 3.4) Pub Date : 2023-09-13 Alessandro Bruschi, Davide Maria Donati, Claudia Di Bella
Patient specific instrumentation (PSI) and intraoperative surgical navigation (SN) can significantly help in achieving wide oncological margins while sparing bone stock in bone tumour resections. This is a systematic review aimed to compare the two techniques on oncological and functional results, preoperative time for surgical planning, surgical intraoperative time, intraoperative technical complications
-
Bone tumor examination based on FCNN-4s and CRF fine segmentation fusion algorithm J. Bone Oncol. (IF 3.4) Pub Date : 2023-09-06 Shiqiang Wu, Xiaoming Bai, Liquan Cai, Liangming Wang, XiaoLu Zhang, Qingfeng Ke, Jianlong Huang
Background and objective Bone tumor is a kind of harmful orthopedic disease, there are benign and malignant points. Aiming at the problem that the accuracy of the existing machine learning algorithm for bone tumor image segmentation is not high, a bone tumor image segmentation algorithm based on improved full convolutional neural network which consists fully convolutional neural network (FCNN-4s) and
-
A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects J. Bone Oncol. (IF 3.4) Pub Date : 2023-09-01 Yanhua Ding, Yusi Liu, Changlin Dou, Shuren Guo
Background Complications of bone metastases such as skeletal-related events lead to the impaired functional status and quality of life including death in patients with bone metastasis from solid tumors. Denosumab (XGEVA®) is indicated for the prevention of skeletal-related events in bone metastasis patients with solid tumors. The biosimilar product LY01011, a fully human anti-receptor activator of
-
DXA assessment and fracture prevention in hormone positive breast cancer patients after treatment initiation with aromatase inhibitors: A registry-based cohort study J. Bone Oncol. (IF 3.4) Pub Date : 2023-08-25 Vanessa Rouach, Yona Greenman, Gabriel Chodick, Inbal Goldshtein
Background Several guidelines have been proposed to prevent aromatase inhibitors induced bone loss (AIBL), but there is scarce data on their endorsement in clinical practice. Aim To assess bone health evaluation and fracture prevention in postmenopausal women with estrogen receptor (ER)-positive breast cancer after aromatase inhibitors (AI) initiation. Methods An historical cohort analysis based on
-
A global bibliometric and visualized analysis of the status and trends of bone metastasis in breast cancer research from 2002 to 2021 J. Bone Oncol. (IF 3.4) Pub Date : 2023-08-23 Li Li, Nengbin Wan, Ying He, Yi Zhang, Xiao He, Lingli Lu
Bone metastasis of breast cancer considerably reduces not only overall survival but also health-related quality of life due to pain, fatigue, and skeletal-related events. Objective: This study aims to analyze the research hotspots and trends of global research on bone metastasis of breast cancer in the past 20 years to provide a reference for relevant personnel in this field to carry out academic research
-
Contrast-enhanced magnetic resonance image segmentation based on improved U-Net and Inception-ResNet in the diagnosis of spinal metastases J. Bone Oncol. (IF 3.4) Pub Date : 2023-08-17 Hai Wang, Shaohua Xu, Kai-bin Fang, Zhang-Sheng Dai, Guo-Zhen Wei, Lu-Feng Chen
Objective The objective of this study was to investigate the use of contrast-enhanced magnetic resonance imaging (CE-MRI) combined with radiomics and deep learning technology for the identification of spinal metastases and primary malignant spinal bone tumor. Methods The region growing algorithm was utilized to segment the lesions, and two parameters were defined based on the region of interest (ROI)
-
Implant failure and revision strategies after total spondylectomy for spinal tumors J. Bone Oncol. (IF 3.4) Pub Date : 2023-08-11 Xianglin Hu, Sean M Barber, Yingzheng Ji, Hongwei Kou, Weiluo Cai, Mo Cheng, Hongjian Liu, Wending Huang, Wangjun Yan
-
Optimal timing for local ablative treatment of bone oligometastases in non-small cell lung cancer J. Bone Oncol. (IF 3.4) Pub Date : 2023-08-02 Jayoung Lee, Jung A. Kim, Tai Joon An, Hyochun Lee, Eun Ji Han, Young Jo Sa, Hyo Rim Kim, Chan Kwon Park, Tae-Jung Kim, Jeong Uk Lim
-
Cav3.2 T-Type calcium channels downregulation attenuates bone cancer pain induced by inhibiting IGF-1/HIF-1α signaling pathway in the rat spinal cord J. Bone Oncol. (IF 3.4) Pub Date : 2023-08-01 Qingying Liu, Zhongyuan Lu, Huan Ren, Lijun Fu, Yueliang Wang, Huilian Bu, Minyu Ma, Letian Ma, Chen Huang, Jian Wang, Weidong Zang, Jing Cao, Xiaochong Fan
Background Bone cancer pain (BCP) is one of the most ubiquitous and refractory symptoms of cancer patients that needs to be urgently addressed. Substantial studies have revealed the pivotal role of Cav3.2 T-type calcium channels in chronic pain, however, its involvement in BCP and the specific molecular mechanism have not been fully elucidated. Methods The expression levels of Cav3.2, insulin-like
-
LINC00482 sponged miR-2467-3p to promote bone metastasis of prostate cancer through activating Wnt/β-catenin signaling pathway J. Bone Oncol. (IF 3.4) Pub Date : 2023-07-21 Shiyao Liao, Xuemei Fang, Kai Zhou, Tingxiao Zhao, Lichen Ji, Wei Zhang, Xugang Zhong, Fabo Feng, Jun Lv, Yao Kang, Danjie Zhu
This study was designed to investigate the biological functions of LINC00482 in prostate cancer (PCa) with bone metastasis. TCGA dataset of PCa was applied for LINC00482 expression analysis and real time PCR was used to verify the expression level of LINC00482 in PCa tissues as well as PCa bone metastatic tissues. To detect the biological functions of LINC00482 in vitro, various assays were used including
-
Analysis of intercellular communication in the osteosarcoma microenvironment based on single cell sequencing data J. Bone Oncol. (IF 3.4) Pub Date : 2023-07-11
Osteosarcoma (OS) is the most common primary bone cancer in children and young adults, patient survival rates have not improved in recent decades. To further understand the interrelationship between different cell types in the tumor microenvironment of osteosarcoma, we comprehensively analyzed single-cell sequencing data from six patients with untreated osteosarcoma. Nine major cell types were identified
-
Imaging evaluation of blood supply changes after chemotherapy of osteosarcoma and its correlation with tumor necrosis rate J. Bone Oncol. (IF 3.4) Pub Date : 2023-07-13 Yongkun Yang, Yuan Li, Xiaohui Niu, Weifeng Liu
Background Analysis of the tumour necrosis rate is an important method to evaluate the effect of neoadjuvant chemotherapy for osteosarcoma. However, at present, there is no specific imaging method to evaluate this effect. The purpose of this study was to evaluate the changes in blood supply after chemotherapy by measuring the CT enhancement rate and to analyse the correlation between the CT enhancement
-
LncRNA SATB2-AS1 promotes tumor growth and metastasis and affects the tumor immune microenvironment in osteosarcoma by regulating SATB2 J. Bone Oncol. (IF 3.4) Pub Date : 2023-06-27 Peipei Wang, Jianwei Zhu, Qingqin Long, Yan Wang, Huihua Xu, Huimin Tao, Biwen Wu, Jiajun Li, Yong Wu, Sihong Liu
Our previous report has identified a lncRNA SATB2-AS1, which was significantly up-regulated in osteosarcoma tissue and promotes the proliferation of osteosarcoma cells in vitro. However, the mechanisms of SATB2-AS1 regulating the growth and metastasis of osteosarcoma cells in vivo and its role in the prognosis of osteosarcoma patients are still unclear. In this study, the transcriptome sequencing data
-
MAT2A inhibits the ferroptosis in osteosarcoma progression regulated by miR-26b-5p J. Bone Oncol. (IF 3.4) Pub Date : 2023-06-23 Shuchi Xia, Yun Liang, Yuqing Shen, Wuxue Zhong, Yiqun Ma
-
Adamantinoma: A review of the current literature J. Bone Oncol. (IF 3.4) Pub Date : 2023-06-22 Sarah Louise Smyth, Ather Siddiqi, Nick Athanasou, Duncan Whitwell, Hooman Soleymani majd
Adamantinoma is a rare primary low-grade malignant tumour of the appendicular skeleton most commonly found in the tibia. It has an indolent course, with local recurrences and lung metastases occurring over a protracted duration. There have been several suggestions pertaining to a vascular origin in the literature, however, histogenesis remains unclear. Currently, guidelines are not available pertaining
-
A Quantitative CT Analysis of Fibula Inlayed in a Massive Allograft for Femoral Diaphysis Reconstruction J. Bone Oncol. (IF 3.4) Pub Date : 2023-06-17 Jan Lesensky, Ana C. Belzarena, Martin Masek, Zdenek Matejovsky jr
Introduction In diaphyseal reconstructions for bone tumor resection, massive bone allografts (MBA) are historically regarded as the gold standard. However, these are not without complications, and they present an elevated risk of infection, nonunion and structural failure that increases over time as the graft remains largely avascular. To counteract this disadvantage, a combination of allograft with
-
CD44 expression is correlated with osteosarcoma cell progression and immune infiltration and affects the Wnt/β-catenin signaling pathway J. Bone Oncol. (IF 3.4) Pub Date : 2023-05-25 Hairu Ji, Lingwei Kong, Yu Wang, Zhiping Hou, Wei Kong, Jiemin Qi, Yu Jin
CD44 is associated with a variety of human diseases and plays a potential role in tumorigenesis, however, the mechanism of its role in osteosarcoma remains unclear. We analyzed the expression of CD44 in the Cancer Genome Atlas (TCGA) and genotype-tissue expression pan-cancer data and found that it was highly expressed in most tumors, including sarcoma. The expression of CD44 in osteosarcoma cell lines
-
Genetic characterization of a novel organoid from human malignant giant-cell tumor J. Bone Oncol. (IF 3.4) Pub Date : 2023-05-25 Rie Suzuki, Toru Wakamatsu, Keiichi Yoshida, Yukiko Matsuoka, Haruna Takami, Sho Nakai, Hironari Tamiya, Shigeki Kakunaga, Toshinari Yagi, Ken-ichi Yoshida, Yoshinori Imura, Yoshihiro Yui, Satoru Sasagawa, Satoshi Takenaka
Malignant giant-cell tumors are extremely rare bone sarcomas that transform from conventional giant-cell tumors during long periods of treatment. Owing to their rarity, no further analysis of their molecular pathogenesis exists, and thus, no standard treatment has been established. Recently, organoid culture methods have been highlighted for recapturing the tumor microenvironment, and we have applied
-
Comprehensive landscape of TGFβ-related signature in osteosarcoma for predicting prognosis, immune characteristics, and therapeutic response J. Bone Oncol. (IF 3.4) Pub Date : 2023-05-12 Dong Liu, Ye Peng, Xian Li, Zhijie Zhu, Zhenzhou Mi, Zhao Zhang, Hongbin Fan
Osteosarcoma (OS) is a highly heterogeneous malignant bone tumor, and its tendency to metastasize leads to a poor prognosis. TGFβ is an important regulator in the tumor microenvironment and is closely associated with the progression of various types of cancer. However, the role of TGFβ-related genes in OS is still unclear. In this study, we identified 82 TGFβ DEGs based on RNA-seq data from the TARGET
-
Therapeutic approaches in patients with bone metastasis due to endometrial carcinoma – A systematic review J. Bone Oncol. (IF 3.4) Pub Date : 2023-05-15 Martin Heidinger, Elisa Simonnet, Li Mei Koh, Brigitte Frey Tirri, Marcus Vetter
-
Deep learning-based magnetic resonance imaging of the spine in the diagnosis and physiological evaluation of spinal metastases J. Bone Oncol. (IF 3.4) Pub Date : 2023-05-09 Dapeng Wang, Yan Sun, Xing Tang, Caijun Liu, Ruiduan Liu
Background and objective Spinal metastasis accounts for 70% of the bone metastases of tumors, so how to diagnose and predict spinal metastasis in time through effective methods is very important for the physiological evaluation of the therapy of patients. Methods MRI scans of 941 patients with spinal metastases from the affiliated hospital of Guilin Medical University were collected, analyzed, and
-
Molecular and biologic biomarkers of Ewing sarcoma: A systematic review J. Bone Oncol. (IF 3.4) Pub Date : 2023-04-26 Mohammad Daher, Ziad Zalaquett, Ralph Chalhoub, Sami Abi Farraj, Majd Abdo, Amer Sebaaly, Hampig-Raphaël Kourie, Ismat Ghanem
With an annual incidence of less than 1%, Ewing sarcoma mainly occurs in children and young adults. It is not a frequent tumor but is the second most common bone malignancy in children. It has a 5-year survival rate of 65–75%; however, it has a poor prognosis when it relapses in patients. A genomic profile of this tumor can potentially help identify poor prognosis patients earlier and guide their treatment
-
Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma J. Bone Oncol. (IF 3.4) Pub Date : 2023-04-18 Yiming Zhang, Wenyi Gan, Nan Ru, Zhaowen Xue, Wenjie Chen, Zihang Chen, Huajun Wang, Xiaofei Zheng
Background Osteosarcoma is one of the most prevalent bone malignancies with a poor prognosis. The N7-methylguanosine (m7G) modification facilitates the modification of RNA structure and function tightly associated with cancer. Nonetheless, there is a lack of joint exploration of the relationship between m7G methylation and immune status in osteosarcoma. Methods With the support of TARGET and GEO databases
-
Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents J. Bone Oncol. (IF 3.4) Pub Date : 2023-04-10 Tomoaki Fukui, Keisuke Oe, Teruya Kawamoto, Masayuki Morishita, Ikuo Fujita, Shunsuke Takahara, Atsushi Sakurai, Takashi Iwakura, Keiji Yoshida, Kenjiro Ito, Etsuo Shoda, Takafumi Hiranaka, Masaya Tsunoda, Ryosuke Kuroda, Takahiro Niikura
Bone-modifying agents (BMAs), with bone-resorptive inhibitory effects, such as zoledronic acid and denosumab, are widely used at higher doses for bone-related events caused by bone metastasis of malignant tumors. These drugs have been suggested to be associated with atypical femoral fractures (AFFs), and the relationship between BMAs and AFFs has attracted attention. To investigate the clinical features
-
How has the field of metastatic breast cancer in bones evolved over the past 22 years? J. Bone Oncol. (IF 3.4) Pub Date : 2023-04-10 Yi Chen, Zhen-Ning Guo, Rong-Quan He, Zhi-Guang Huang, Jia-Yuan Luo, Wei Tang, Su-Ning Huang, Gang Chen
Background Although knowledge on metastatic breast cancer in bones (MBCB) has increased rapidly over the past 22 years, a comprehensive and objective bibliometric analysis is still lacking. Materials and methods We used R, VOSviewer, and Citespace software to conduct a bibliometric analysis of 5,497 papers on MBCB from the Web of Science Core Collection (WOSCC) using author, institution, country/region
-
The validity of the distress thermometer in patients with musculoskeletal tumors J. Bone Oncol. (IF 3.4) Pub Date : 2023-04-10 Finn Marie Uhlenbruch, Nikolas Schopow, Elisabeth Roschke, Christian Lycke, Christoph-Eckhard Heyde, Anja Mehnert-Theuerkauf, Georg Osterhoff
Background Visits to an outpatient cancer clinic represent a challenging situation for patients, which can trigger anxiety and helplessness in those affected. It is important to identify patients with high psychological distress as early as possible in order to provide them with supportive psychological interventions. The aim of this study was to validate the Distress Thermometer (DT), a widely used
-
Molecular imaging of bone metastasis J. Bone Oncol. (IF 3.4) Pub Date : 2023-04-05 Eliana Khojasteh, Farrokh Dehdashti, Monica Shokeen
Recent advances in molecularly targeted modular designs for in vivo imaging applications has thrusted open possibilities of investigating deep molecular interactions non-invasively and dynamically. The shifting landscape of biomarker concentration and cellular interactions throughout pathological progression requires quick adaptation of imaging agents and detection modalities for accurate readouts
-
Single-cell RNA-seq reveals intratumoral heterogeneity in osteosarcoma patients: A review J. Bone Oncol. (IF 3.4) Pub Date : 2023-03-20 Dylan D. Thomas, Ryan A. Lacinski, Brock A. Lindsey
-
YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522 J. Bone Oncol. (IF 3.4) Pub Date : 2023-03-05 Darrell Green, Archana Singh, Victoria L. Tippett, Luke Tattersall, Karan M. Shah, Chileleko Siachisumo, Nicole J. Ward, Paul Thomas, Simon Carter, Lee Jeys, Vaiyapuri Sumathi, Iain McNamara, David J. Elliott, Alison Gartland, Tamas Dalmay, William D. Fraser
Primary bone cancer (PBC) comprises several subtypes each underpinned by distinctive genetic drivers. This driver diversity produces novel morphological features and clinical behaviour that serendipitously makes PBC an excellent metastasis model. Here, we report that some transfer RNA-derived small RNAs termed tRNA fragments (tRFs) perform as a constitutive tumour suppressor mechanism by blunting a
-
Innovation in proximal femoral replacement for oncology patients—A novel eggshell procedure J. Bone Oncol. (IF 3.4) Pub Date : 2023-02-28 Jiazheng Zhao, Xiaowei Ma, Helin Feng
Purpose Proximal femoral replacement (PFR) for oncology patients is gaining interest as a limb salvage operation due to its obvious advantages. However, almost all hip replacement surgeries including PFR, are faced with the challenge of how to reconstruct the functional musculature in an optimal way. To address the challenge, we have developed an innovative eggshell procedure and through this study
-
Indirect bilirubin impairs invasion of osteosarcoma cells via inhibiting the PI3K/AKT/MMP-2 signaling pathway by suppressing intracellular ROS J. Bone Oncol. (IF 3.4) Pub Date : 2023-02-23 Xuhui Yuan, Cong Ma, Jiayu Li, Junhong Li, Ronghui Yu, Feng Cai, Gaoyang Qu, Bo Yu, Lang Liu, Duo Zeng, QuanHui Jiao, Qi Liao, Xiaobin Lv
Background Osteosarcoma is most prevalently found primary malignant bone tumors, with primary metastatic patients accounting for approximately 25% of all osteosarcoma patients, yet their 5-year OS remains below 30%. Bilirubin plays a key role in oxidative stress-associated events, including malignancies, making the regulation of its serum levels a potential anti-tumor strategy. Herein, we investigated
-
The role and mechanism of JAK2/STAT3 signaling pathway regulated by m6A methyltransferase KIAA1429 in osteosarcoma J. Bone Oncol. (IF 3.4) Pub Date : 2023-02-17 Jiaquan Luo, Xuhua Wang, Zhaoyuan Chen, Huaqiang Zhou, Yihui Xiao
Osteosarcoma (OS) is the most malignant bone tumor which mainly occurs in childhood or adolescence. The previous studies indicated that OS is difficult to treat. KIAA1429 is one of the components of m6A complex that regulating the process of m6A modification, which plays a crucial role in tumorigenesis. But the mechanism of KIAA1429 regulating OS cell identity was not entirely clear, which needs further
-
Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis J. Bone Oncol. (IF 3.4) Pub Date : 2023-02-09 Justin-Pierre Lorange, Jose Ramirez Garcia Luna, Frédéric Grou-Boileau, Derek Rosenzweig, Michael H. Weber, Elie Akoury
Background While considered the mainstay of treatment for specific bone metastases, ZA is used predominantly to treat osteolytic lesions. The purpose of this network meta-analysis is to compare ZA to other treatment options in its ability to improve specific clinical outcomes in patients with bone metastases secondary to any primary tumor. Methods PubMed, Embase and Web of Science were systematically
-
Surgical margin assessment of bone tumours: A systematic review of current and emerging technologies J. Bone Oncol. (IF 3.4) Pub Date : 2023-02-09 Haitham Shoman, Jawad Al-Kassmy, Maryam Ejaz, Justin Matta, Sandi Alakhras, Kalin Kahla, Mario D'Acunto
Osteosarcoma is the most common malignant tumour of the bone. Complete surgical excision is critical to achieve optimal outcomes and lower recurrence rates. However, accurate assessment of tumour margins remains a challenge and multiple technologies are employed for this purpose. The aim of this study is to highlight current and emerging technologies and their efficacy in detecting clear bone margins
-
Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway J. Bone Oncol. (IF 3.4) Pub Date : 2023-01-03 Zhun Wei, Di Zheng, Wenfeng Pi, Yonglong Qiu, Kezhou Xia, Weichun Guo
Currently, chemotherapeutic drugs are widely used for the treatment of osteosarcoma. However, many of these drugs exhibit shortcomings such as poor efficacy, high toxicity, and tolerance. Isoquercitrin (ISO) is a traditional Chinese medicine that has been proved to exert good therapeutic effects on various tumors; however, its role in osteosarcoma has not been reported. Here, we observed that ISO exerted
-
Diagnostic value of H3F3A mutation and clinicopathological features of giant cell tumours in non-long bones J. Bone Oncol. (IF 3.4) Pub Date : 2022-12-22 Yanli Luo, Juan Tang, Jin Huang, Dingjun Hu, Yueqing Bai, Jie Chen, Keyang Sun, Huizhen Zhang, Zhiyan Liu
Aims A histone H3F3A (H3.3) mutation involving a substitution in H3.3 G34 recently has been reported in GCTB within the frequency range (from 69 % to 96 %) and is a helpful diagnostic indicator of GCTB. However, the relationship between H3F3A mutations and the clinicopathological feature of GCTB involving non-long bones (irregular bones and small bones) is unclear. Methods and results H3F3A mutations